GVS
GVS develops and manufactures filtration and separation solutions and microporous membranes for healthcare, life-science, energy, mobility, and safety industries.
- Public company
- Zola Predosa, ITItaly
GVS develops and manufactures filtration and separation solutions and microporous membranes for healthcare, life-science, energy, mobility, and safety industries.
gvs.comCrawled Nov 2, 2026
GVS Group serves the Healthcare & Life Sciences, Energy & Mobility, and Health & Safety sectors with filtration solutions.
GVS provides a product catalog of highly technological filtration solutions for various industries.
Consult GVS product catalog: highly technological filtration solutions for MedTech, Energy & Mobility and Safety sectors.
GVS Group offers filtration solutions through its Health & Safety, Healthcare & Life Sciences, and Energy & Mobility divisions.
Candida species are among the top five infectious bloodstream pathogens and remain the most common cause of invasive fungal infections, a early diagnosis is critical for appropriate patient management and for improving the outcomes of candidemia.
WHO is evaluating the separation of the Omicron Variant into BA.1 and BA.2: the GVS Flame CoViD -19 VARIANTS qPCR Master Kit - CE-IVD is able to identify both, drastically reducing the risk of false negatives.
Drinking water is an essential resource, as it is fundamental to life and health. However, despite the rigorous controls required by national and European laws, it is at risk of contamination by dangerous and persistent substances known as PFAS.
From November 16 to 19, GVS MedTech will be in Düsseldorf for COMPAMED 2026, one of the leading international platforms for innovation and technologies in the medical sector.
Consult GVS group News & Media. Highly technological filtration solutions for Healthcare & Life Sciences, Energy & Mobility and Health & Safety sectors.
The company lists job opportunities and accepts spontaneous applications.
The page displays open job opportunities and active recruitment by area and country.
The audit board comprises three regular members and two alternates, as per the company’s bylaws.
The company’s board of directors consists of five to nine members.
The company’s board of directors includes five to nine members, appointed by shareholders.
Pursuant to Article 23 of the By-Laws, the Board of Statutory Auditors comprises three Statutory Auditors and two Alternate Auditors.
GVS evolved from supplying healthcare components to offering advanced filtration solutions for multiple industries.
GVS Group is one of the world's leading manufacturers of filter solutions for Healthcare & Life Sciences, Energy & Mobility and Health & Safety sectors.
The Group is aware of its social, environmental and economic impact and pays special attention to these themes.
The Group is constantly engaged in maintaining and strengthening the governance, in line with the national and international best practices.
The company’s experts provide information about GVS products and the industries it operates in.
The company’s experts provide information about GVS products and the industries it serves.
GVS Group provides investor relations contacts and offers highly technological filtration solutions for various industries.
GVS Group offers investor relations contacts and provides highly technological filtration solutions across multiple sectors.
1.1 Capitalized terms contained in these standard Terms and Conditions for the supply of Goods and Services shall have the following meanings:
Consult the statute in force since the Society stock market flotation and the documents about the procedures approved by the Board of Directors.
GVS MedTech showcases its advancements in respiratory care and diagnostics at **COMPAMED 2026**, a major medical technology trade event in Düsseldorf. The company engages with global manufacturers, developers, and industry professionals to explore collaborations and innovations in the MedTech sector. The event runs from November 16 to 19, serving as a key platform for networking and knowledge exchange.
Oct 2026GVSNews article
GVS Transfusion Medicine exhibits at the **AABB Annual Meeting 2026**, a leading global event for blood banking, transfusion medicine, and biotherapies. The conference in **Atlanta, Georgia (October 17–19, 2026)** attracts healthcare professionals, researchers, and industry leaders to discuss advancements in the field. The company engages with attendees to showcase its contributions to transfusion medicine innovation.
Oct 2026GVSNews article
GVS reframes its valuation narrative following improved profitability in its half-year earnings report. The company highlights stronger financial performance as a key factor in its revised market positioning.
Aug 2026Yahoo FinanceNews article
GVS reports **3.3% organic growth** in the first half of 2026, alongside an expansion in margins to **93%**. The company’s financial update highlights improved profitability while sustaining revenue growth.
Aug 2026Investing.comNews article